Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Myriam Curet sold 4,198 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $3.16, for a total value of $13,265.68. Following the completion of the sale, the director now directly owns 31,777 shares of the company's stock, valued at approximately $100,415.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Nektar Therapeutics Price Performance
NASDAQ NKTR opened at $3.08 on Tuesday. The business has a 50 day simple moving average of $4.10 and a 200 day simple moving average of $4.26. Nektar Therapeutics has a one year low of $3.02 and a one year high of $19.37. The stock has a market capitalization of $577.21 million, a P/E ratio of -1.09 and a beta of 1.16.
Get Nektar Therapeutics alerts:Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.16. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The business had revenue of $21.59 million during the quarter, compared to analysts' expectations of $22.75 million. During the same quarter last year, the firm posted ($0.69) earnings per share. The firm's revenue was down 23.8% on a year-over-year basis. Equities analysts expect that Nektar Therapeutics will post -2.14 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on NKTR. JPMorgan Chase & Co. cut Nektar Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Monday, August 8th. StockNews.com raised Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, August 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $13.17.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Calton & Associates Inc. bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Vantage Consulting Group Inc bought a new position in Nektar Therapeutics in the second quarter worth approximately $41,000. Arete Wealth Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $59,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $61,000. Institutional investors own 96.99% of the company's stock.
Nektar Therapeutics Company Profile
(Get Rating)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
See Also
- Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.